Acquisition Pending
Kuva Labs acquisition of Lisata Therapeutics
Announced 6 Mar 2026 · NASDAQ: LSTA · US$4.00 cash per share
Advisers
Lisata Therapeutics
Target
- Financial adviser
- Legal adviser
- Fairness opinion
Kuva Labs
Acquirer
- Legal adviser
- Shackelford, McKinley & Norton, LLP
- Information Agent for the Offer
- Target
- Lisata Therapeutics
- Acquirer
- Kuva Labs
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Passage Bio and Remix Therapeutics merger Jun 2026 · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Rallybio acquisition of Avenzo Therapeutics Jun 2026 · Biotech
Sources
- 9 Mar 2026 Press release (EX-99.1, exhibit), Lisata Therapeutics Enters into Definitive Agreement to be Acquired by sec.gov
- 10 Jun 2026 Tender offer statement (SC TO-T), LISATA THERAPEUTICS, INC. sec.gov
- 10 Jun 2026 Target response to tender offer (SC 14D9), LISATA THERAPEUTICS, INC. sec.gov

